SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...

The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis and immune modulation, addressing ...

Please provide your email address to receive an email when new articles are posted on . The classically defined diffuse subtype of juvenile systemic sclerosis demonstrates more globally severe disease ...

Dr John Snowden, Consultant Haematologist and Director of Blood and Marrow Transplant at Sheffield Teaching Hospitals, said: ...

High serum type I interferon (IFN) scores, measured through six chemokines, correlated with poorer lung function and health-related quality of life in patients with diffuse cutaneous systemic ...

Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...

Systemic sclerosis, or scleroderma, causes the hardening of skin and connective tissues. Often, the disease harms other organs, such as the heart, kidneys, lungs, and gastrointestinal tract, and it ...

AMSTERDAM — For patients with diffuse cutaneous systemic sclerosis, an autoimmune disease for which there are few treatment options, lenabasum (JBT-101, Corbus Pharmaceuticals) shows potential, new ...

Please provide your email address to receive an email when new articles are posted on . Although lenabasum failed to meet its efficacy endpoint in a trial of patients with diffuse cutaneous systemic ...

Kristina Hamilton, who has Diffuse Systemic Scleroderma, tied the knot with Chris Swanson on April 6 at Trinity Oaks of Matthew's Hope in Cocoa, Florida The wedding was provided at no charge to the ...